MedPath

A Clinical trial to study the effects of a unani formulation 'Diabeat'in patients with high blood sugar levels (Type 2 diabetes mellitus )

Phase 2
Completed
Registration Number
CTRI/2009/091/000702
Lead Sponsor
Hamdard National Foundation New DElhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

1. Patients of type-2 diabetes mellitus, age 30-60 years taking Metformin for more than 3 months with uncontrolled hyperglycaemia i.e.HbA1C between 7% to 9% and Body Mass Index (BMI) between 25-29.9 kg/m2.

2. Patients who are able and willing to follow anti-diabetic therapy under a stable life style and diabetic diet.

3.Patients who are willing and able to understand and follow the protocol and provide informed consent.

Exclusion Criteria

1.History of treatment with any insulin

2.Diabetes mellitus with complications

3.Pregnant or Lactating women

4.Women of childbearing potential who do not take adequate contraceptive protection.

5.History of hypersensitivity to the Metformin or to drug with similar chemical structure.

6.History of any severe systemic disease.

7.Patients with uncontrolled hypertension.

8.History of drug or alcohol abuse.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean HbA1C 6.5%Timepoint: 12 weeks
Secondary Outcome Measures
NameTimeMethod
To achieve a good glycemic control (FPG-80-120 mg/dl; PPG-80-140 mg/dl)Timepoint: 4,8,12 week
© Copyright 2025. All Rights Reserved by MedPath